Search results
Results from the WOW.Com Content Network
On Thursday, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported third-quarter adjusted EPS of $12.46, up 8% year-over-year, beating the consensus of $11.69. The company reported sales of $3.72 ...
On Friday, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion recommending ...
Shares of Regeneron were down over 2% in premarket trading. Eylea, jointly developed with Bayer AG, has driven Regeneron's earnings for years, but sales have now come under pressure, partly from ...
For premium support please call: 800-290-4726 more ways to reach us
Regeneron stock surges on positive results in eye disease drug trial. September 8, 2022 at 12:57 PM ...
For premium support please call: 800-290-4726 more ways to reach us
Regeneron's COVID-19 drug sales drove revenue and EPS.
Regeneron invested $119.5 million in Truveta’s Series C funding round, while Illumina chipped in $20 million. In addition, 17 of Truveta’s 30 partner health systems collectively contributed ...